title: Impact of angina frequency on health utility values of patients with chronic stable angina.
abstract: BACKGROUND
  Chronic angina is a profoundly symptomatic disease. We evaluated the relationship between angina frequency and health utility.
  
  
  METHODS
  We used data from stable angina patients reporting ≥3 attacks/week enrolled in the Efficacy of Ranolazine in Chronic Angina (ERICA) trial. Angina frequency was classified using the Seattle Angina Questionnaire angina frequency (SAQAF) domain into no (100); monthly (61-99); weekly (31-60); and daily (0-30) angina. EuroQol (EQ)-5D health utility scores were derived from SAQ data using two mapping equations. Median EQ-5D utility scores for each SAQAF classification after the 6-week trial period were calculated (reported as: Equation 1/Equation 2). Changes in EQ-5D utility scores from baseline to end-of-trial for patients achieving and not achieving a ≥20-point improvement in SAQAF score and improving and not improving ≥1 SAQAF classification were compared.
  
  
  RESULTS
  Median EQ-5D utility scores (n = 548) were 0.68/0.60. Compared to patients reporting no angina symptoms (n = 28; 0.89/0.87) patients reporting monthly (n = 188; 0.80/0.76), weekly (n = 283; 0.72/0.65) and daily (n = 49; 0.65/0.54) symptoms had poorer health utility (p < 0.001 for both equations). Patients improving ≥1SAQAF classification (n = 254/541, 47%) experienced a median 0.05/0.07 greater improvement in EQ-5D health utility compared to those not improving ≥1 classification (p < 0.001 for both equations). Patients improving ≥20-points on the SAQAF (n = 355/541, 66%) experienced a median 0.06/0.07 greater improvement in health utility compared to those not achieving a ≥20-point improvement (p < 0.001 for both).
  
  
  CONCLUSIONS
  Chronic angina patient health utility decreases as angina frequency increases. Patients reporting clinically important improvement in angina frequency experience a tangible improvement in health utility.
  
  
  BACKGROUND
  NCT00091429.
authors.forename: Christine G
authors.initials: CG
authors.lastname: Kohn
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Parker
authors.forename: Brendan L
authors.initials: BL
authors.lastname: Limone
authors.affiliation: University of Connecticut School of Pharmacy, Storrs, CT, USA. Craig.Coleman@hhchealth.org.
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use; D060050:Angina, Stable / Q000188:drug therapy / Q000473:pathology / Q000523:psychology*; D002908:Chronic Disease / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D010919:Placebos; D011788:Quality of Life; D000069458:Ranolazine; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D010919:Placebos; D000069458:Ranolazine